__timestamp | Celldex Therapeutics, Inc. | Dynavax Technologies Corporation |
---|---|---|
Wednesday, January 1, 2014 | 104381000 | 84580000 |
Thursday, January 1, 2015 | 100171000 | 86943000 |
Friday, January 1, 2016 | 102726000 | 84493000 |
Sunday, January 1, 2017 | 96171000 | 64988000 |
Monday, January 1, 2018 | 66449000 | 74951000 |
Tuesday, January 1, 2019 | 42672000 | 62331000 |
Wednesday, January 1, 2020 | 42534000 | 28607000 |
Friday, January 1, 2021 | 53311000 | 32228000 |
Saturday, January 1, 2022 | 82258000 | 46600000 |
Sunday, January 1, 2023 | 118011000 | 54886000 |
Unleashing the power of data
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Celldex Therapeutics, Inc. and Dynavax Technologies Corporation have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Celldex consistently outspent Dynavax, with an average annual R&D expenditure of approximately 30% more. Notably, in 2023, Celldex's R&D spending surged to its highest, marking a 40% increase from its 2020 low. Meanwhile, Dynavax's R&D investment peaked in 2015 but has since seen a gradual decline, dropping by nearly 35% by 2023. This trend highlights Celldex's aggressive pursuit of innovation, while Dynavax appears to be adopting a more conservative approach. As the biotech landscape continues to shift, these spending patterns may offer insights into each company's strategic priorities and future growth potential.
Analyzing R&D Budgets: Merck & Co., Inc. vs Celldex Therapeutics, Inc.
Research and Development Investment: Amgen Inc. vs Celldex Therapeutics, Inc.
Zoetis Inc. vs Celldex Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for GSK plc and Dynavax Technologies Corporation
Analyzing R&D Budgets: Takeda Pharmaceutical Company Limited vs Celldex Therapeutics, Inc.
argenx SE or Celldex Therapeutics, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Viatris Inc. and Celldex Therapeutics, Inc.
Research and Development Investment: Corcept Therapeutics Incorporated vs Dynavax Technologies Corporation
Rhythm Pharmaceuticals, Inc. or Dynavax Technologies Corporation: Who Invests More in Innovation?
Research and Development Expenses Breakdown: HUTCHMED (China) Limited vs Celldex Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for ImmunityBio, Inc. and Celldex Therapeutics, Inc.
Comparing Innovation Spending: Celldex Therapeutics, Inc. and MiMedx Group, Inc.